April 5, 2018 09:03 AM EDTUpdated 09:42 AM

$21B or bust! AbbVie ensures its blockbuster US marathon on Humira will run into 2023

John Carroll

Editor & Founder

AbbVie has finished another big section in its great wall of protective IP deals that will keep the world’s biggest blockbuster unmarked by biosimilar competition …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

$21B or bust! AbbVie ensures its blockbuster US marathon on Humira will run into 2023

John Carroll

Editor & Founder

Sign up to read this article for free.

Safety concerns and trial holds for pediatric RSV vaccines prompt caution from FDA adcomm

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

'Serious liver injury' cases lead FDA to call for monitoring of Ocaliva patients

Pfizer shares positive Phase 3 results in breast cancer subset

Lonza looks to depart capsule and health ingredients as it undergoes restructure

The key to faster, more impactful research? Put patients in the driver’s seat

$21B or bust! Ab­b­Vie en­sures its block­buster US marathon on Hu­mi­ra will run in­to 2023

John Carroll

Editor & Founder

Sign up to read this article for free.

Safe­ty con­cerns and tri­al holds for pe­di­atric RSV vac­cines prompt cau­tion from FDA ad­comm

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

'Se­ri­ous liv­er in­jury' cas­es lead FDA to call for mon­i­tor­ing of Ocali­va pa­tients

Pfiz­er shares pos­i­tive Phase 3 re­sults in breast can­cer sub­set

Lon­za looks to de­part cap­sule and health in­gre­di­ents as it un­der­goes re­struc­ture

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

$21B or bust! AbbVie ensures its blockbuster US marathon on Humira will run into 2023

Safety concerns and trial holds for pediatric RSV vaccines prompt caution from FDA adcomm

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

'Serious liver injury' cases lead FDA to call for monitoring of Ocaliva patients

Pfizer shares positive Phase 3 results in breast cancer subset

Lonza looks to depart capsule and health ingredients as it undergoes restructure

The key to faster, more impactful research? Put patients in the driver’s seat